HPV vaccines

As of September 2026, there are eight HPV vaccines with marketing authorisation that are manufactured directly by the authorisation holder: Bivalent: Cecolin ® (Innovax), Cervarix ® (GSK), Walrinvax ® (Walvax) ; Quadrivalent: Gardasil ® (MSD), Cervavac (SII), Tsegardex ® (Nanolek); Nonavalent: Gardasil-9 ® (MSD), Cecolin 9® (Innovax).^{Go to footnote 11}. Six of those vaccines are WHO-prequalified.^{Go to footnote 22, Go to footnote 33}

Other HPV vaccines are authorised or commercialised under local brand names through technology-transfer, bulk-transfer, licensing, distribution or localisation arrangements (e.g., Nusagard in Indonesia, Silgard in Argentina, Papilovax in Bangladesh). For these products, the available public evidence indicates local commercialisation and/or partial local manufacturing steps but does not consistently demonstrate full end-to-end production─ including drug-substance manufacture ─ by the local commercialising entity.^{Go to footnote 11} 

Detailed information on the different products can be found in the vaccine comparison table.^{Go to footnote 44}